Alison Muir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alison Muir has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Elijah Raphael Behr
Cardiovascular Research Institute, School of Health and Medical Sciences, City St. George’s, University of London, United Kingdom (J.P.R.W., E.R.B., C.J.C., R.W.).
2 shared publications - Amanda M. Varnava
National Heart and Lung Institute, Imperial College, London, UK (A.A., J.S.M., A.M.V.).
1 shared publication - Andrew D. Krahn
Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
1 shared publication - Bo Gregers Winkel
Department of Cardiology, The Heart Centre, Copenhagen University Hospital - Rigshospitalet , Copenhagen 2100
1 shared publication - Bode Ensam
Cardiovascular and Genomics Research Institute, School of Health and Medical Sciences, City St. George's, University of London , Cranmer Terrace, London, SW17 0RE
1 shared publication - Carla M. Haglund-Turnquist
Departments of Cardiovascular Medicine, Pediatric and Adolescent Medicine, and Molecular Pharmacology and Experimental Therapeutics; Divisions of Heart Rhythm Services and Pediatric Cardiology, Windland Smith Rice Genetic Heart Rhythm Clinic, Mayo Clinic, Rochester, MN (C. Bell, J.M.B., B.C.C., C.H.-T., M.J.A.).
1 shared publication
Latest Publications
- Open Access
- 18 May 2023
- Published by Elsevier in Heart Rhythm
- Vol. 20 (5) , S105
EN-452414-5 VENTRICULAR CONDUCTION IS A MARKER FOR ARRHYTHMIC RISK IN OVERLAP SODIUM CHANNEL DISEASE
- 18 May 2023
- Published by Elsevier in Heart Rhythm
- Vol. 20 (5) , S105
Open AccessEN-452414-5 VENTRICULAR CONDUCTION IS A MARKER FOR ARRHYTHMIC RISK IN OVERLAP SODIUM CHANNEL DISEASE
- 8 February 2023
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 138 (2) , 82
Implementation and clinical utility of stability and severity scoring systems in the Fabry disease cohort in Northern Ireland
- 8 February 2023
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 138 (2) , 82
Implementation and clinical utility of stability and severity scoring systems in the Fabry disease cohort in Northern Ireland
- Open Access
- 1 December 2022
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 15 (12) , e011263
The Utility of Sodium Channel Provocation in Unexplained Cardiac Arrest Survivors and Electrocardiographic Predictors of Ventricular Fibrillation Recurrence
Background: The implications of a drug-induced type 1 Brugada ECG pattern following sodium channel blocker provocation (SCBP) are not fully understood. Methods: Baseline clinical and ECG data were obtained from consecutive unexplained cardiac arrest survivors undergoing SCBP at 3 centers. A further 15 SCBP positive (SCBP+) unexplained cardiac arrest survivors were recruited from 3 additional centers to explore ventricular fibrillation recurrence. Results: A total of 121 consecutive unexplained cardiac arrest survivors underwent SCBP. The yield of the drug-induced type 1 Brugada ECG pattern was 17%. A baseline type 2/3 Brugada pattern (T2/3BP) (adjusted odds ratio, 19.36 [2.74–136.61]; P =0.003) and PR interval (odds ratio, 1.03 [1.01–1.05] per ms; P =0.017) were independent predictors of SCBP+ response. A pathogenic SCN5A variant was identified in 36% of the SCBP+ group versus 0% in the SCBP− group ( P P =0.011) and the presence of global early repolarization (hazard ratio, 7.91 [3.22–19.44]; P P =0.055). Conclusions: The yield of the drug-induced type 1 Brugada ECG pattern in consecutive unexplained cardiac arrest survivors undergoing SCBP is 17%. A baseline T2/3BP and PR interval were independent predictors of the drug-induced type 1 Brugada ECG pattern. Greater heritability of BrS phenotype in this group was evidenced by a greater prevalence of pathogenic SCN5A variants and relatives with a type 1 Brugada pattern. A history of prior syncope and the presence of global early repolarization were independent predictors of ventricular fibrillation recurrence.
- 1 December 2022
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 15 (12) , e011263
Open AccessThe Utility of Sodium Channel Provocation in Unexplained Cardiac Arrest Survivors and Electrocardiographic Predictors of Ventricular Fibrillation Recurrence
Background: The implications of a drug-induced type 1 Brugada ECG pattern following sodium channel blocker provocation (SCBP) are not fully understood. Methods: Baseline clinical and ECG data were obtained from consecutive unexplained cardiac arrest survivors undergoing SCBP at 3 centers. A further 15 SCBP positive (SCBP+) unexplained cardiac arrest survivors were recruited from 3 additional centers to explore ventricular fibrillation recurrence. Results: A total of 121 consecutive unexplained cardiac arrest survivors underwent SCBP. The yield of the drug-induced type 1 Brugada ECG pattern was 17%. A baseline type 2/3 Brugada pattern (T2/3BP) (adjusted odds ratio, 19.36 [2.74–136.61]; P =0.003) and PR interval (odds ratio, 1.03 [1.01–1.05] per ms; P =0.017) were independent predictors of SCBP+ response. A pathogenic SCN5A variant was identified in 36% of the SCBP+ group versus 0% in the SCBP− group ( P P =0.011) and the presence of global early repolarization (hazard ratio, 7.91 [3.22–19.44]; P P =0.055). Conclusions: The yield of the drug-induced type 1 Brugada ECG pattern in consecutive unexplained cardiac arrest survivors undergoing SCBP is 17%. A baseline T2/3BP and PR interval were independent predictors of the drug-induced type 1 Brugada ECG pattern. Greater heritability of BrS phenotype in this group was evidenced by a greater prevalence of pathogenic SCN5A variants and relatives with a type 1 Brugada pattern. A history of prior syncope and the presence of global early repolarization were independent predictors of ventricular fibrillation recurrence.
- 2 August 2013
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 7 (4) , 497-499
Genetic Biomarkers in Cardiovascular Disease
- 2 August 2013
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 7 (4) , 497-499
Genetic Biomarkers in Cardiovascular Disease